Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Gastroesophageal Reflux Disease (GERD)
Clinical Trial
NCT00787891Last updated: 12/5/2025
JNJ
Johnson & Johnson